Impact of Switching from Twice-Daily Basal Insulin to Once-Daily Insulin Glargine 300 U/mL in People with Type 1 Diabetes on Basal–Bolus Insulin: Phase 4 OPTIMIZE Study

INTRODUCTION: OPTIMIZE evaluated the efficacy, safety and treatment satisfaction of insulin glargine 300 U/mL once daily (Gla-300 OD) in people with type 1 diabetes mellitus (T1DM) previously uncontrolled on basal insulin twice daily (BID) as part of basal–bolus therapy. METHODS: OPTIMIZE was a 28-w...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabetes Ther
Päätekijät: Mathieu, Chantal, Weisnagel, S. John, Stella, Peter, Bruhwyler, Jacques, Alexandre, Kathy
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6995801/
https://ncbi.nlm.nih.gov/pubmed/31925722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00749-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia